The stack addresses both energy intake and energy expenditure simultaneously through independent pathways tirzepatide reduces consumption, 5-amino-1MQ increases cellular fat burning creating complementary rather than overlapping effects
NNMT inhibition reduces consumption of nicotinamide (and of S-adenosylmethionine) by blocking the enzyme that would otherwise methylate them
Blocks the NNMT enzyme to support fat loss and metabolism Free Shipping on orders over $200 Scan the QR code on any vial to verify its batch, COA, and origin in seconds
We know how urgent it may be, so were shipping ultra fast
The SURMOUNT-1 trial demonstrated 20.9% mean body weight reduction with tirzepatide 15mg weekly at 72 weeks, while preclinical 5-amino-1MQ studies showed visceral fat reduction independent of caloric restriction
06 Confusion between routes Subcutaneous, oral, transdermal, and intranasal AOD-9604 use very different doses